Literature DB >> 8845307

Inhibition of in vitro myogenic differentiation by cellular transcription factor E2F1.

J Wang1, K Helin, P Jin, B Nadal-Ginard.   

Abstract

Terminal differentiation of cultured myocytes requires withdrawal of the cells from the cell cycle. Constitutive overexpression of several oncogenes in myoblasts can inhibit in vitro myogenesis. Here we studied the role of the cellular transcription factor E2F1 on myogenic differentiation. E2F1 expression is irreversibly down-regulated during differentiation of C2C12 myocytes. Furthermore, deregulated E2F1 expression in C2C12 cells prevented myogenic differentiation. This inhibition of myogenesis was associated with the repression of myogenin expression and an elevated cyclin D1 expression. Moreover, E2F1-overexpressing myocytes failed to exit the cell cycle under differentiation conditions. These results are consistent with the notion that E2F1 can function as an oncogene and further suggest that E2F1 down-regulation is required for myogenic differentiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8845307

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  21 in total

1.  The p44/wdr77-dependent cellular proliferation process during lung development is reactivated in lung cancer.

Authors:  Z Gu; F Zhang; Z-Q Wang; W Ma; R E Davis; Z Wang
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

2.  Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation.

Authors:  Blanca Scheijen; Marieke Bronk; Tiffany van der Meer; René Bernards
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

3.  MyoD synergizes with the E-protein HEB beta to induce myogenic differentiation.

Authors:  Maura H Parker; Robert L S Perry; Mélanie C Fauteux; Charlotte A Berkes; Michael A Rudnicki
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

4.  Adenoviral delivery of E2F-1 directs cell cycle reentry and p53-independent apoptosis in postmitotic adult myocardium in vivo.

Authors:  R Agah; L A Kirshenbaum; M Abdellatif; L D Truong; S Chakraborty; L H Michael; M D Schneider
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

5.  Control of proliferation, endoreduplication and differentiation by the Arabidopsis E2Fa-DPa transcription factor.

Authors:  Lieven De Veylder; Tom Beeckman; Gerrit T S Beemster; Janice de Almeida Engler; Sandra Ormenese; Sara Maes; Mirande Naudts; Els Van Der Schueren; Annie Jacqmard; Gilbert Engler; Dirk Inzé
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

6.  Differential impact of RB status on E2F1 reprogramming in human cancer.

Authors:  Christopher McNair; Kexin Xu; Amy C Mandigo; Matteo Benelli; Benjamin Leiby; Daniel Rodrigues; Johan Lindberg; Henrik Gronberg; Mateus Crespo; Bram De Laere; Luc Dirix; Tapio Visakorpi; Fugen Li; Felix Y Feng; Johann de Bono; Francesca Demichelis; Mark A Rubin; Myles Brown; Karen E Knudsen
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

7.  E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα.

Authors:  Lei Zhang; Qian Zhou; Ning Zhang; Weixu Li; Meidan Ying; Wanjing Ding; Bo Yang; Qiaojun He
Journal:  Cell Cycle       Date:  2014-02-17       Impact factor: 4.534

8.  Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction.

Authors:  T Fujimoto; K Anderson; S E W Jacobsen; S-I Nishikawa; C Nerlov
Journal:  EMBO J       Date:  2007-04-12       Impact factor: 11.598

9.  Coupling of caspase-9 to Apaf1 in response to loss of pRb or cytotoxic drugs is cell-type-specific.

Authors:  Andrew T Ho; Qin H Li; Razqallah Hakem; Tak W Mak; Eldad Zacksenhaus
Journal:  EMBO J       Date:  2004-01-08       Impact factor: 11.598

10.  Protease Omi facilitates neurite outgrowth in mouse neuroblastoma N2a cells by cleaving transcription factor E2F1.

Authors:  Qi Ma; Qing-song Hu; Ran-jie Xu; Xue-chu Zhen; Guang-hui Wang
Journal:  Acta Pharmacol Sin       Date:  2015-08       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.